Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005106 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
A Phase 4 study of HIV Infections, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 4
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT00005106 is a Phase 4 study of HIV Infections that has completed, run by Glaxo Wellcome. The registered enrollment target is 230 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00005106, a Phase 4 study of HIV Infections, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.
Conditions Studied
Interventions
- DRUG Lamivudine
- DRUG Stavudine
- DRUG Nelfinavir mesylate
- DRUG Lamivudine/Zidovudine
- DRUG Abacavir sulfate
Study Locations (20)
Florida
- IDC Research Initiative - Altamonte Springs
- Children's Diagnostic Treatment Ctr - Fort Lauderdale
- Community Health Care - Fort Lauderdale
- Comprehensive Care Center - Fort Lauderdale
- Univ of Miami School of Medicine - Miami
- South Shore Hosp - Miami
- Orange County Health Dept - Orlando
- Immunity Care and Research Inc - Plantation
- Daniel Seekins - Tampa
California
- Longbeach Memorial Med Ctr - Longbeach
- Good Samaritan Hosp - Los Angeles
- THE Clinic - Los Angeles
- AIDS Healthcare Foundation - Los Angeles
- Maxine Liggins - Los Angeles
- UCLA Care Ctr - Los Angeles
- Highland Gen Hosp / San Francisco Gen Hosp - Oakland
- San Francisco Gen Hosp - San Francisco
Alabama
- Univ of Alabama at Birmingham - Birmingham
Arizona
- Arizona Clinical Research Ctr Inc - Tucson
District of Columbia
- Georgetown Univ Med Ctr - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 1999-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005106
The ClinicalTrials.gov registry entry for NCT00005106 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (48% lower). The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Lamivudine is the first listed.
NCT00005106 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00005106 about?
NCT00005106 is a clinical study titled "A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients". The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.
What is the current status of trial NCT00005106?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 230 participants. The study started on 1999-09.
What conditions does trial NCT00005106 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00005106?
The interventions under investigation include: Lamivudine (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG), Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00005106?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005106 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.